Abbvie ((ABBV)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

Sutro Biopharma ($STRO) announced an update on their ongoing clinical study. Study Overview: Sutro Biopharma is conducting a Phase 1 open-label ...

SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon tissue SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc (BIOR). (Nasdaq: BIOR), the biotech ...

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...

Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for Full Enrollment by Year-End 2025 “The latest data presented at EHA today continue to demonstrate divesiran’s ...

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery ...

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) -Clinical data to date supports a potentially ...

Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for Full Enrollment by Year-End 2025 LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (“Silence” or the “Company”) ...